



Gel strength and gelation kinetics as parameters in the development and quality control of hydrogels for medical products

Therese Andersen, Jan Egil Melvik and Michael Dornish FMC BioPolymer/NovaMatrix Industriveien 33, Sandvika, Norway

ASTM Scaffolds Workshop, 21 May 2013, Indianapolis IN





Disclosure


- The authors are employed by FMC BioPolymer AS.
- NovaMatrix, a business unit of FMC BioPolymer, manufactures, characterizes, documents, and sells ultrapure alginate, hyaluronan, fucoidan, and watersoluble chitosan salts for biomedical applications.
- Alginate-based ionically cross-linked gel formulations are enabling technologies





The old

> Alginate microbeads for cell encapsulatioin








Applications using cell encapsulation

DISEASE	PRODUCER CELLS	SUBSTANCE SECRETED	
Cancer	Genetically manipulated cells	Angiostatin, endostatin, cytokines	
Cancer	Hybridoma Mab's		
Diabetes	Islets of Langerhans	Insulin	
Parkinson's	Adrenal chromaffin cells	Dopamine	
Chronic pain	Multiple cell types	Endorphin, enkephalin	
Hypocalcemia	Parathyroid cells	PTH	
Liver failure	Hepatocytes	Artificial Organ	
Tissue repair	Chondrocytes	Tissue regeneration	






Encapsulated cells







Inhomogeneous vs homogeneous gelling







Strength and stability

High strength/stability factors

- High G-content
- Average G-block content about 15
- Not MW-dependent above certain value
- High affinity cations (Sr²⁺, Ba²⁺, Ca²⁺)
- Coating with polycation


Low strength/stability factors

- Chelating compounds (phosphate, citrate, lactate)
- Non-gelling ions (ratio non-gelling/gelling)
- Swelling properties





Alginate hydrogel bead characterization




Typical behavior of a viscoelastic material under the stress relaxation test. f_i is the initial load, f_{eq} is the load or stress at equilibrium, and f_{pk} is the peakload





Stress relaxation testing



Stress relaxation test for samples in CaCl₂, a) Mean force, b) Mean displacement





The new


Self-gelling alginate







Rheology measurements of self-gelling alginate




Parameter	Description
FG	Final Gel strength given as Elastic Modulus at completed gelling
FGT1/2	Time (minutes) to obtain 50% of Final gel elastic modulus(G')
FGT98%	Time (minutes) to achieve 98% of Final gel elastic modulus(G')






Effect of alginate composition







Effect of molar mass







The future


> Alginate foam scaffolds
















Alginate foam as a cell scaffold




515/30


x,y:100 um





Cell/tissue growth in alginate scaffolds





Multinucleated myotubes – C2C12 mouse myoblasts (Day 60)





Alginate scaffold product testing

Properties	Internal Specification	External Specification
Cell distribution	> 300 µm at day 1	Conforms
Cell Viability	> 70% at day 15 (live/dead)	Conforms
Cell Proliferation	Should have doubled in number in 14 days	Conforms
Absorption volume	12-well: 200 ± 20 µl 24-well: 100 ± 10 µl 96-well: 10 ± 2 µl	N/A
CaCO ₃ residues	Score ≥ 3	N/A
Air bubbles	Score ≥ 3	N/A
Sterility	No growth, 20 kGy	No growth, 20 kGy







PRODUCT RELEASE REPORT

Product name: NovaMatrix®-3D cell culture kit

Batch no: BU-

Generic name: NovaMatrix®-3D kit

Storage conditions: 2 - 8 °C

Packaging material: Glass vial and plastic multi-well plate Manufacturing site: FMC BioPolymer AS d/b/a NovaMatrix

<u>Test</u>	Result	Specification	Method
Freeze-dried alginate vial Apparent viscosity	52	40 – 80 mPas	AM-056
Alginate foam			
Cell distribution	Pass	> 300 µm at day 1	401007
Cell viability	Pass	> 80 % at day 15	401007
Cell proliferation	Pass	minimum 1 population doubling in 14 days	401007
Sterility	No growth	No growth	401010


AM: FMC BioPolymer AS / NovaMatrix Standard Method

Date
Michael Dornish Scientific Director





Elasticity of some tissue compared with materials used in TE



Kolahi KS, Donjacour A, Liu X, Lin W, et al. (2012) Effect of Substrate Stiffness on Early Mouse Embryo Development. PLoS ONE 7(7): e41717. doi:10.1371/journal.pone.0041717

http://www.plosone.org/article/info:doi/10.1371/journal.pone.0041717







Conclusions

- Hydrogels are already in clinical trials
- Application-specific product specifications
- BUT no universal testing methodology